ROCKVILLE, Md., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will conduct a conference call for invited analysts and institutional investors on October 13, 2011 at 10:30 am ET to review the recent top-line results from a Phase I clinical trial of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate. Participating on the call will be Gregory M. Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, and Pedro A. Piedra, M.D., Professor at Baylor College of Medicine in the Department of Molecular Virology and Microbiology.
